GlassScriptPhysician profile
Samuel MD Fox
NPI 1881891240
$2,046.22
in general payments reported to CMS, 2019-2025
28 companies · $540 in 2025
The $540 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $182 · 2021: $518 · 2023: $341 · 2024: $465 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Entertainment: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.56 |
| Entertainment | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $466.56 | 2020-2025 | Wegovy |
| Hologic Sales and Service, LLC | $329.35 | 2021 | |
| Abbott Laboratories | $180.43 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $137.49 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $113.58 | 2025 | Austedo Xr |
| Amgen INC. | $86.44 | 2023-2025 | Evenity, Prolia, Otezla |
| Lundbeck LLC | $85.66 | 2023-2024 | Rexulti |
| Indivior INC. | $78.16 | 2024-2025 | Sublocade |
| Gilead Sciences, INC. | $61.65 | 2025 | |
| Zealand Pharma US, INC. | $57.08 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.87 | 2024-2025 | |
| Astellas Pharma US INC | $37.30 | 2023-2024 | Veozah |
| Phadia US INC. | $35.47 | 2024-2025 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $35.39 | 2023 | Farxiga, Fasenra |
| Otsuka America Pharmaceutical, INC. | $35.16 | 2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.33 | 2025 | Auvelity |
| Optos, INC. | $26.70 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $23.54 | 2024 | |
| Orexo US, INC. | $22.55 | 2023 | Zubsolv |
| Lilly USA, LLC | $21.87 | 2023 | Jardiance |
| Almatica Pharma LLC | $21.64 | 2024 | Loreev Xr |
| Dexcom, INC. | $21.05 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $19.81 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.05 | 2023 | Seglentis |
| Exact Sciences Corporation | $16.75 | 2023 | Cologuard Collection Kit |
| Axonics, INC. | $15.45 | 2023 | Axonics |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.90 | 2023 | |
| Echosens North America, INC. | $9.99 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.